图书馆订阅: Guest
Begell Digital Portal Begell 数字图书馆 电子图书 期刊 参考文献及会议录 研究收集
医药载体系统评论综述
影响因子: 2.9 5年影响因子: 3.72 SJR: 0.573 SNIP: 0.551 CiteScore™: 2.43

ISSN 打印: 0743-4863
ISSN 在线: 2162-660X

医药载体系统评论综述

DOI: 10.1615/CritRevTherDrugCarrierSyst.2017018693
pages 257-282

Lipid Nanoparticles for Nasal/Intranasal Drug Delivery

S. Cunha
UCIBIO, ReQuimTe, Laboratory of Pharmaceutical Technology/Centre of Research in Pharmaceutical Sciences, Faculty of Pharmacy, Porto University, Porto, Portugal
M. H. Amaral
UCIBIO, ReQuimTe, Laboratory of Pharmaceutical Technology/Centre of Research in Pharmaceutical Sciences, Faculty of Pharmacy, Porto University, Porto, Portugal
J. M. Sousa Lobo
UCIBIO, ReQuimTe, Laboratory of Pharmaceutical Technology/Centre of Research in Pharmaceutical Sciences, Faculty of Pharmacy, Porto University, Porto, Portugal
Ana C. Silva
UCIBIO, ReQuimTe, Laboratory of Pharmaceutical Technology/Centre of Research in Pharmaceutical Sciences, Faculty of Pharmacy, Porto University, Porto, Portugal; UFP Energy, Environment and Health Research Unit (FP-ENAS), Universidade Fernando Pessoa, Porto, Portugal

ABSTRACT

Studies on the development of drug delivery systems have increased because these systems have particular characteristics that allow them to improve therapeutics. Among these, lipid nanoparticles (solid lipid nanoparticles, SLNs; and nanostructured lipid carriers, NLCs) have demonstrated suitability for drug targeting. The nasal administration of drug-loaded lipid nanoparticles showed effectiveness in treating central nervous system (CNS) disorders, particularly neurodegenerative diseases, because the nasal route (also called intranasal route) allows direct nose-to-brain drug delivery by means of lipid nanoparticles. Nonetheless, the feasibility of this application remains an open field for researchers. Drawbacks must be overcome before reaching the clinic (e.g., drug absorption at subtherapeutic levels, rapid mucociliary clearance). The intranasal administration of drugs for systemic absorption is effective for treating other conditions, such as cardiovascular diseases, infections, severe pain, and menopausal syndrome. In the near future, it is expected that patients will benefit from the advantages of lipid nanoparticle–based formulations, via the nasal/intranasal route, which bypasses the blood-brain barrier (BBB), avoiding first-pass metabolism and gastrointestinal degradation. This review discusses the use of SLNs and NLCs for nasal drug administration. A brief description of the nasal route and the features of SLNs and NLCs is initially provided.


Articles with similar content:

Mucosal Drug Delivery: Membranes, Methodologies, and Applications
Critical Reviews™ in Therapeutic Drug Carrier Systems, Vol.21, 2004, issue 3
Bozena Michniak, Yifan Song, Rashmi Thakur, Victor M. Meidan, Yiping Wang
Nanostructured Delivery Systems: Augmenting the Delivery of Antiretroviral Drugs for Better Management of HIV/AIDS
Critical Reviews™ in Therapeutic Drug Carrier Systems, Vol.32, 2015, issue 6
Sanaul Mustafa, Roopa S Pai, Gurinder Singh
Updated Progress of Nanocarrier-Based Intranasal Drug Delivery Systems for Treatment of Brain Diseases
Critical Reviews™ in Therapeutic Drug Carrier Systems, Vol.35, 2018, issue 5
Min Chen, Ying Fan, Xuefeng Xia, Wen Wu, Philippe Maincent, Jinqiang Zhang
Perspectives of Lipid-Based Drug Carrier Systems for Transdermal Delivery
Critical Reviews™ in Therapeutic Drug Carrier Systems, Vol.35, 2018, issue 4
Shikha Srivastava, Madhulika Pradhan, Shailendra Saraf, Deependra Singh, Swarnlata Saraf, Manju Rawat Singh
Functional Polymeric Nanoparticles: An Efficient and Promising Tool for Active Delivery of Bioactives
Critical Reviews™ in Therapeutic Drug Carrier Systems, Vol.23, 2006, issue 4
Senthilkumar Murugesan, Tathagata Dutta, Abhay Asthana, Manoj Tare, Surbhi Saraf, Narendra Kumar Jain, Vijayaraj Rajkumar, Manoj Nahar, Dinesh Mishra